Clinical Trial Update: Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating iodine-131 labeled metaiodobenzylguanidine (MIBG) in patients with recurrent or refractory neuroblastoma, malignant pheochro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Iodine-131 Metaiodobenzylguanidine (metaiodobenzylguanidine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma, Pheochromocytoma | Phase 2 | Status: RECRUITING